Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Expanded Prostate Cancer Index Composite

Known as: EPIC, Expanded Prostate Cancer Index Composite (EPIC) 
A self-administered questionnaire designed to evaluate patient function and bother after prostate cancer treatment.
National Institutes of Health

Related topics

Related topics

19 relations
Ability to Control Urination QuestionBody Weight Gain Exceeding 10 PoundsBody Weight Loss Exceeding 10 PoundsDissatisfied - response
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years
Importance Understanding the adverse effects of contemporary approaches to localized prostate cancer treatment could inform… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2016
Highly Cited
2016
Focal irreversible electroporation for prostate cancer: functional outcomes and short-term oncological control
Background:Current data on the use of irreversible electroporation (IRE) in the treatment of prostate cancer (PCa) is limited. We… Expand
  • table 1
  • table 2
  • table 5
  • table 3
  • table 4
Highly Cited
2015
Highly Cited
2015
Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non…
Summary Background Patient-reported outcomes (PROs) might detect more toxic effects of radiotherapy than do clinician-reported… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Highly Cited
2013
Highly Cited
2013
Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials.
PURPOSE To evaluate the early and late health-related quality of life (QOL) outcomes among prostate cancer patients following… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
Highly Cited
2012
Highly Cited
2012
Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study
Summary Background Radical whole-gland therapy can lead to significant genitourinary and rectal side-effects for men with… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Highly Cited
2012
Highly Cited
2012
Hypofractionated stereotactic body radiotherapy in low‐risk prostate adenocarcinoma
Recent reports using extreme hypofractionated regimens in the treatment of low‐risk prostate adenocarcinoma have been encouraging… Expand
Highly Cited
2012
Highly Cited
2012
High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial.
PURPOSE There are multiple treatment options for favorable-risk prostate cancer. High-dose-rate (HDR) brachytherapy as a… Expand
Highly Cited
2011
Highly Cited
2011
Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients…
PURPOSE Measuring the health related quality of life of patients with prostate cancer in routine clinical practice is hindered by… Expand
Highly Cited
2011
Highly Cited
2011
Five year Expanded Prostate cancer Index Composite‐based quality of life outcomes after prostatectomy for localized prostate cancer
Study Type – Therapy (outcomes research) Level of Evidence 2c 
Highly Cited
2008
Highly Cited
2008
Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer.
PURPOSE To compare treatment impact on health-related quality of life (HRQL) in patients with localized prostate cancer, from… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE